Through innovative science, compassion, and a relentless commitment to progress, we aim to transform the lives of those affected by ALS. We are developing Mitometin, a small molecule drug, to be a truly disease-modifying therapeutic. We are driven by our profound desire to make a genuine difference for people living with this unforgiving brain disease and strongly believe that our work to develop new medicine to treat ALS will yield insights applicable to other neurological disorders.
